Rhenman & Partners Asset Management AB Lowers Position in Agios Pharmaceuticals Inc (AGIO)

Share on StockTwits

Rhenman & Partners Asset Management AB lowered its stake in Agios Pharmaceuticals Inc (NASDAQ:AGIO) by 12.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 127,012 shares of the biopharmaceutical company’s stock after selling 18,416 shares during the period. Rhenman & Partners Asset Management AB owned 0.22% of Agios Pharmaceuticals worth $5,857,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of AGIO. First Trust Advisors LP increased its holdings in shares of Agios Pharmaceuticals by 58.8% in the third quarter. First Trust Advisors LP now owns 1,162,010 shares of the biopharmaceutical company’s stock valued at $89,614,000 after purchasing an additional 430,216 shares in the last quarter. Capital International Investors increased its holdings in shares of Agios Pharmaceuticals by 10.4% in the third quarter. Capital International Investors now owns 3,096,422 shares of the biopharmaceutical company’s stock valued at $238,796,000 after purchasing an additional 291,393 shares in the last quarter. Vanguard Group Inc increased its holdings in shares of Agios Pharmaceuticals by 2.7% in the third quarter. Vanguard Group Inc now owns 4,251,439 shares of the biopharmaceutical company’s stock valued at $327,871,000 after purchasing an additional 109,849 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Agios Pharmaceuticals by 2.7% in the third quarter. Vanguard Group Inc. now owns 4,251,439 shares of the biopharmaceutical company’s stock valued at $327,871,000 after purchasing an additional 109,849 shares in the last quarter. Finally, FMR LLC increased its holdings in shares of Agios Pharmaceuticals by 0.7% in the third quarter. FMR LLC now owns 8,698,886 shares of the biopharmaceutical company’s stock valued at $670,858,000 after purchasing an additional 58,043 shares in the last quarter. 95.40% of the stock is owned by institutional investors and hedge funds.

AGIO opened at $53.36 on Monday. Agios Pharmaceuticals Inc has a 52 week low of $41.63 and a 52 week high of $99.82. The firm has a market cap of $3.10 billion, a price-to-earnings ratio of -7.91 and a beta of 2.38.

A number of analysts recently weighed in on AGIO shares. BidaskClub raised shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, January 17th. ValuEngine lowered shares of Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, January 4th. Zacks Investment Research lowered shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, January 2nd. Oppenheimer reaffirmed a “hold” rating on shares of Agios Pharmaceuticals in a report on Friday, November 16th. Finally, Cowen reaffirmed a “buy” rating on shares of Agios Pharmaceuticals in a report on Friday, November 2nd. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and eight have issued a buy rating to the company. Agios Pharmaceuticals currently has an average rating of “Hold” and an average target price of $100.13.

TRADEMARK VIOLATION WARNING: This piece was reported by Zolmax and is the property of of Zolmax. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at https://zolmax.com/investing/rhenman-partners-asset-management-ab-lowers-position-in-agios-pharmaceuticals-inc-agio/2891846.html.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.

See Also: Do back-end load funds outperform no-load funds?

Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals Inc (NASDAQ:AGIO).

Institutional Ownership by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Piedmont Office Realty Trust  Upgraded to Strong-Buy at Zacks Investment Research
Piedmont Office Realty Trust Upgraded to Strong-Buy at Zacks Investment Research
61,239 Shares in Comstock Resources Inc  Acquired by Raymond James Financial Services Advisors Inc.
61,239 Shares in Comstock Resources Inc Acquired by Raymond James Financial Services Advisors Inc.
Zacks Investment Research Lowers OneMain  to Sell
Zacks Investment Research Lowers OneMain to Sell
Rexnord  Stock Rating Lowered by Zacks Investment Research
Rexnord Stock Rating Lowered by Zacks Investment Research
THC Biomed Intl   Shares Down 7%
THC Biomed Intl Shares Down 7%
Black Knight  Issues  Earnings Results
Black Knight Issues Earnings Results


Leave a Reply

 
© 2006-2019 Zolmax.